Dr Sadeka Afrin Losy, MD (Neurology) 3rd Part, Mymensingh Medical College Hospital (MMCH), Mymensingh, Bangladesh; E-mail:
Mymensingh Med J. 2024 Jul;33(3):643-648.
Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease with unknown etiology. Some previous studies suggest that elevated serum homocysteine level is a risk factor for stroke, ischemic heart disease; atherosclerosis and neurodegenerative diseases like Parkinson's disease. Serum homocysteine level relates with Parkinson's disease through various mechanisms including gene defect, apoptosis, oxidative stress and DNA damage. Some recent studies reveal that serum homocysteine level is elevated in Parkinson's disease patient compared to healthy individuals. This study was aimed to compare the serum homocysteine level in Parkinson's disease patients and age and sex matched apparently healthy individuals. This was a case control study which was conducted in Department of Neurology and Medicine, Mymensingh Medical College Hospital, Mymensingh during November 2019 to April 2021. Total 55 cases of Parkinson's disease patients and age and sex matched 55 apparently healthy controls were enrolled in this study. Demographics and clinical data were collected using structured case record form and adopting purposive type of sampling method. Serum homocysteine level was measured in both case and control groups. The study reveals that, average age of the patients and control group was in sixth decade. Male predominance was found with male to female ratio was 1.5:1 in case group. Both groups showed almost similar demographic profiles. Twenty-nine (52.72%) patients of Parkinson's disease observed higher serum homocysteine level in contrast to only 8(14.54%) in control group. The mean serum homocysteine ±SD was 15.43±6.04μmol/L in case group and 10.04±5.31μmol/L in control group; the difference was statistically significant (p=0.001). Mean serum homocysteine levels were measured progressively higher with increased duration and advanced stages of disease. It was concluded that, serum homocysteine level is higher in Parkinson's disease patients than normal healthy individuals. In addition, there was significant positive correlation of elevated serum homocysteine with increased duration of Parkinson's disease and advanced stages of the disease.
帕金森病（PD）是一种慢性、进行性神经退行性疾病，病因不明。一些先前的研究表明，血清同型半胱氨酸水平升高是中风、缺血性心脏病、动脉粥样硬化和帕金森病等神经退行性疾病的危险因素。血清同型半胱氨酸水平通过基因缺陷、细胞凋亡、氧化应激和 DNA 损伤等多种机制与帕金森病有关。一些最近的研究表明，帕金森病患者的血清同型半胱氨酸水平高于健康人。本研究旨在比较帕金森病患者与年龄和性别相匹配的健康个体的血清同型半胱氨酸水平。这是一项病例对照研究，于 2019 年 11 月至 2021 年 4 月在孟加拉国迈门辛医科大学医院神经内科进行。共纳入 55 例帕金森病患者和 55 例年龄和性别相匹配的健康对照者。采用结构化病例记录表格收集人口统计学和临床数据，并采用目的性抽样方法。在病例组和对照组中均测量了血清同型半胱氨酸水平。研究表明，患者和对照组的平均年龄均在 60 岁左右。病例组中男性居多，男女比例为 1.5:1。两组的人口统计学特征几乎相似。与对照组的 8 例（14.54%）相比，帕金森病患者中有 29 例（52.72%）观察到较高的血清同型半胱氨酸水平。病例组的平均血清同型半胱氨酸±SD 为 15.43±6.04μmol/L，对照组为 10.04±5.31μmol/L；差异具有统计学意义（p=0.001）。随着疾病持续时间的延长和疾病阶段的进展，平均血清同型半胱氨酸水平逐渐升高。研究结果表明，帕金森病患者的血清同型半胱氨酸水平高于正常健康人。此外，血清同型半胱氨酸水平升高与帕金森病持续时间的延长和疾病阶段的进展呈显著正相关。
